Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized open-label first-line CLL trial comparing standard chemoimmunotherapy with venetoclax-based combinations
MOH_2017-06-19_000525Phase 3Not yet recruiting
- Sponsor
- German CLL Study Group
- Start
- May 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of venetoclax, rituximab, obinutuzumab, ibrutinib, fludarabine and 2 more in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) (4 arms), sponsored by German CLL Study Group. Planned start May 2017; status: not yet recruiting.
02
Drugs
venetoclaxrituximabobinutuzumabibrutinibfludarabine
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on MOH_2017-06-19_000525.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-06-19_000525.